Home
Home
Contact
Careers
Terms and Conditions
Privacy Policy
Cookie Policy
YouTube
X
LinkedIn
About Arcturus
RNA Medicines
Technologies
Pipeline
Clinical Trials
Business Development
Publications
Investor Relations

Comparison of the immunogenicity of bivalent self-amplifying mRNA and mRNA vaccines against various SARS-CoV-2 variants up to six months postvaccination.

October 14, 2024

Home
Contact
Careers
Terms and Conditions
Privacy Policy
Cookie Policy
YouTube
X
LinkedIn
© 2026 Arcturus Therapeutics, Inc.